{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T22:23:38Z","timestamp":1783463018505,"version":"3.55.0"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:00:00Z","timestamp":1773964800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019717","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019717","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are currently recommended as one of the four pillars of treatment in heart failure (HF) with reduced ejection fraction (HFrEF). Following the approval of dapagliflozin in 2020, real-world data are relevant for the medical community and payers. This study aimed to characterize the patient population with dapagliflozin initiated for HFrEF in clinical practice in 9 countries from Central Eastern Europe and the Baltic Area (CEE-BA).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>EVOLUTION-HF CEE-BA is a multicentre, multi-country, observational, longitudinal study conducted in 102 centres in Bulgaria, Croatia, Estonia, Hungary, Latvia, Lithuania, Poland, Romania, and Slovenia. All treatment decisions were at the discretion of the patient\u2019s healthcare providers, based on the locally approved product information and routine clinical practice. Patients with type 1 diabetes, prior treatment with dapagliflozin or other SGLT2i, and initiation of dapagliflozin outside the approved HFrEF indication were excluded. The baseline period covered 12 months prior to dapagliflozin initiation, with prospective follow-up continuing up to 12 months or until loss to follow-up, death, or study discontinuation, whichever occurred first. Descriptive statistics and Kaplan\u2013Meier methods were used.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 1131 patients with HFrEF were included in the full analysis set. Ischaemic aetiology was present in 52% of patients. The mean left ventricular ejection fraction was 32%. The most frequent comorbidities were atrial fibrillation (46%), type 2 diabetes (37%), and chronic kidney disease (29%). At the time of dapagliflozin initiation, 93% of patients received any combination of a renin\u2013angiotensin\u2013aldosterone system inhibitor (RAASi), beta-blocker (BB), or mineralocorticoid receptor antagonists (MRA). Of all patients, 60% received concomitantly all three classes plus dapagliflozin for their HFrEF. Except for dapagliflozin, which was administered as 10\u2005mg\/day, optimal doses were recorded for 14% for any RAASi, 17% for BB, and 25% for MRA. At 6- and 12-month follow-up, maintenance of dapagliflozin treatment was recorded in 95% and 96% of patients, respectively. The real-world median time to discontinuation of dapagliflozin has not been reached. The percentage of patients receiving all four classes recommended in HFrEF remained stable over the study period. Adverse events were reported spontaneously, as in routine clinical practice in each centre.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This large non-interventional study provides a contemporary perspective of the treatments used in HFrEF over 1-year follow-up. Despite high dapagliflozin persistence rates, a low proportion of patients received complete guideline-directed medical therapy in optimal doses. Improvement of HF management decisions across the CEE-BA region is warranted.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/eschf\/xvag085","type":"journal-article","created":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T12:49:50Z","timestamp":1773838190000},"source":"Crossref","is-referenced-by-count":2,"title":["Real-world evidence with dapagliflozin in heart failure with reduced ejection fraction in Central Eastern Europe and the Baltic region (EVOLUTION-HF CEE-BA Study)"],"prefix":"10.1093","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4529-2687","authenticated-orcid":false,"given":"Przemys\u0142aw","family":"Leszek","sequence":"first","affiliation":[{"name":"Heart Failure Transplantology and Mechanical Circulatory Support Department, National Institute of Cardiology , Alpejska 42, 04-628 Warsaw ,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoltan","family":"Csan\u00e1di","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Faculty of Medicine, University of Debrecen , Debrecen ,","place":["Hungary"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Gruev","sequence":"additional","affiliation":[{"name":"Cardiology Department, National Multiprofile Transport Hospital \u2018Tsar Boris III\u2019 Sofia , Sofia ,","place":["Bulgaria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiina","family":"Uuetoa","sequence":"additional","affiliation":[{"name":"Cardiology Center, Confido Medical Centre , Tallinn ,","place":["Estonia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"\u017daliaduonyt\u0117","sequence":"additional","affiliation":[{"name":"Heart Center, Lithuanian University of Health Sciences, Medical Academy , Kaunas ,","place":["Lithuania"]},{"name":"Heart Center, Kaunas Hospital of Lithuanian University of Health Science , Kaunas ,","place":["Lithuania"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davor","family":"Mili\u010di\u0107","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Diseases, University Hospital Centre Zagreb, University of Zagreb School of Medicine , Zagreb ,","place":["Croatia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K\u0101rlis","family":"Tru\u0161inskis","sequence":"additional","affiliation":[{"name":"Latvian Center of Cardiology, Pauls Stradi\u0146\u0161 Clinical University Hospital , Riga ,","place":["Latvia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u016brat\u0117","family":"Baukien\u0117","sequence":"additional","affiliation":[{"name":"Medical Affairs, AstraZeneca , Vilnius ,","place":["Lithuania"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandru Mihai","family":"Isvoranu","sequence":"additional","affiliation":[{"name":"Medical Affairs , AstraZeneca, Bucharest ,","place":["Romania"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3197-3628","authenticated-orcid":false,"given":"Ovidiu","family":"Chioncel","sequence":"additional","affiliation":[{"name":"Department Cardiology 1, \u2018C.C. Iliescu\u2019 Institute of Cardiovascular Diseases , Bucharest ,","place":["Romania"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,3,20]]},"reference":[{"key":"2026051414200205900_xvag085-B1","doi-asserted-by":"publisher","first-page":"e11","DOI":"10.15420\/cfr.2023.05","article-title":"Global public health burden of heart failure: an updated review","volume":"9","author":"Shahim","year":"2023","journal-title":"Card Fail Rev"},{"key":"2026051414200205900_xvag085-B2","doi-asserted-by":"publisher","first-page":"3068","DOI":"10.1161\/01.cir.0000039105.49749.6f","article-title":"Lifetime risk for developing congestive heart failure: the Framingham heart study","volume":"106","author":"Lloyd-Jones","year":"2002","journal-title":"Circulation"},{"key":"2026051414200205900_xvag085-B3","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.cardfail.2024.07.001","article-title":"HF STATS 2024: heart failure epidemiology and outcomes statistics an updated 2024 report from the heart failure society of America","volume":"31","author":"Bozkurt","year":"2025","journal-title":"J Card Fail"},{"key":"2026051414200205900_xvag085-B4","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1093\/nutrit\/nuac058","article-title":"Association between dietary patterns and depression: an umbrella review of meta-analyses of observational studies and intervention trials","volume":"81","author":"Gianfredi","year":"2023","journal-title":"Nutr Rev"},{"key":"2026051414200205900_xvag085-B5","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1093\/eurpub\/ckad059","article-title":"Challenges in heart failure care in four European countries: a comparative study","volume":"33","author":"Steiner","year":"2023","journal-title":"Eur J Public Health"},{"key":"2026051414200205900_xvag085-B6","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1002\/ejhf.2143","article-title":"The heart failure association atlas: heart failure epidemiology and management statistics 2019","volume":"23","author":"Seferovi\u0107","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026051414200205900_xvag085-B7","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1002\/ejhf.813","article-title":"Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC heart failure long-term registry","volume":"19","author":"Chioncel","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2026051414200205900_xvag085-B8","doi-asserted-by":"publisher","first-page":"e026708","DOI":"10.1161\/JAHA.122.026708","article-title":"Persistent high burden of heart failure across the ejection fraction Spectrum in a nationwide setting","volume":"11","author":"Stolfo","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"2026051414200205900_xvag085-B9","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1016\/j.jacc.2007.04.064","article-title":"Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF registry","volume":"50","author":"Fonarow","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"2026051414200205900_xvag085-B10","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"2026051414200205900_xvag085-B11","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"2026051414200205900_xvag085-B12","doi-asserted-by":"publisher","first-page":"6956","DOI":"10.3390\/jcm12226956","article-title":"New challenges in heart failure with reduced ejection fraction: managing worsening events","volume":"12","author":"Lavalle","year":"2023","journal-title":"J Clin Med"},{"key":"2026051414200205900_xvag085-B13","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1002\/ejhf.3295","article-title":"How to tackle therapeutic inertia in heart failure with reduced ejection fraction. A scientific statement of the Heart Failure Association of the ESC","volume":"26","author":"Savarese","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026051414200205900_xvag085-B14","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"2026051414200205900_xvag085-B15","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"2026051414200205900_xvag085-B16","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1007\/s40265-023-01887-4","article-title":"Guideline-directed medical therapy for the treatment of heart failure with reduced ejection fraction","volume":"83","author":"Patel","year":"2023","journal-title":"Drugs"},{"key":"2026051414200205900_xvag085-B17","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.jchf.2021.09.004","article-title":"A systematic review and network meta-analysis of pharmacological treatment of heart failure with reduced ejection fraction","volume":"10","author":"Tromp","year":"2022","journal-title":"JACC Heart Fail"},{"key":"2026051414200205900_xvag085-B18","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1016\/S0140-6736(22)02076-1","article-title":"Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial","volume":"400","author":"Mebazaa","year":"2022","journal-title":"Lancet"},{"key":"2026051414200205900_xvag085-B19","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1007\/s10741-023-10325-2","article-title":"Guideline-directed medical therapy for HFrEF: sequencing strategies and barriers for life-saving drug therapy","volume":"28","author":"Malgie","year":"2023","journal-title":"Heart Fail Rev"},{"key":"2026051414200205900_xvag085-B20","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1016\/j.jchf.2023.04.017","article-title":"Mortality, outcomes, costs, and use of medicines following a first heart failure hospitalization: EVOLUTION HF","volume":"11","author":"Bozkurt","year":"2023","journal-title":"JACC Heart Fail"},{"key":"2026051414200205900_xvag085-B21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jchf.2022.08.009","article-title":"Heart failure drug treatment-inertia, titration, and discontinuation: a multinational observational study (EVOLUTION HF)","volume":"11","author":"Savarese","year":"2023","journal-title":"JACC Heart Fail"},{"key":"2026051414200205900_xvag085-B22","author":"AstraZeneca Press Release"},{"key":"2026051414200205900_xvag085-B23","author":"FDA"},{"key":"2026051414200205900_xvag085-B24","author":"AstraZeneca Press Release"},{"key":"2026051414200205900_xvag085-B25","author":"European Medicines Agency"},{"key":"2026051414200205900_xvag085-B26","author":"FDA"},{"key":"2026051414200205900_xvag085-B27","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1161\/CIRCULATIONAHA.119.044138","article-title":"Effects of dapagliflozin on symptoms, function, and quality of life in patients with heart failure and reduced ejection fraction: results from the DAPA-HF trial","volume":"141","author":"Kosiborod","year":"2020","journal-title":"Circulation"},{"key":"2026051414200205900_xvag085-B28","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1002\/ehf2.14687","article-title":"Heart failure care in the Central and Eastern Europe and Baltic region: status, barriers, and routes to improvement","volume":"11","author":"Chioncel","year":"2024","journal-title":"ESC Heart Fail"},{"key":"2026051414200205900_xvag085-B29","doi-asserted-by":"publisher","first-page":"ii86","DOI":"10.1093\/eurheartjsupp\/suae036.207","article-title":"Use of dapagliflozin for heart failure with reduced ejection fraction in Italian clinical practice (EVOLUTION\u2013HF ITALY): interim analysis at 6 months of follow-up","volume":"26","author":"Orso","year":"2024","journal-title":"Eur Heart Journal Suppl"},{"key":"2026051414200205900_xvag085-B30","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehae666.1092","article-title":"Clinical characteristics and treatment patterns of new users of dapagliflozin for heart failure with reduced ejection fraction: an observational study programme across 12 countries (EVOLUTION HF)","volume":"45","author":"Rosano","year":"2024","journal-title":"Eur Heart J"},{"key":"2026051414200205900_xvag085-B31","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1002\/ejhf.1858","article-title":"Epidemiology of heart failure","volume":"22","author":"Groenewegen","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026051414200205900_xvag085-B32","doi-asserted-by":"publisher","first-page":"3522","DOI":"10.3390\/jcm13123522","article-title":"Safety and efficacy of dapagliflozin in patients with heart failure with reduced ejection fraction: multicentre retrospective study on echocardiographic parameters and biomarkers of heart congestion","volume":"13","author":"Battistoni","year":"2024","journal-title":"J Clin Med"},{"key":"2026051414200205900_xvag085-B33","doi-asserted-by":"publisher","first-page":"3859","DOI":"10.1093\/eurheartj\/ehz835","article-title":"Sex differences in heart failure","volume":"40","author":"Lam","year":"2019","journal-title":"Eur Heart J"},{"key":"2026051414200205900_xvag085-B34","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1002\/ejhf.3039","article-title":"Non-cardiac comorbidities and intensive up-titration of oral treatment in patients recently hospitalized for heart failure: insights from the STRONG-HF trial","volume":"25","author":"Chioncel","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026051414200205900_xvag085-B35","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1002\/ejhf.3404","article-title":"Status and timing of angiotensin receptor-neprilysin inhibitor implementation in patients with heart failure and reduced ejection fraction: data from the Swedish Heart Failure Registry","volume":"26","author":"Stolfo","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026051414200205900_xvag085-B36","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.18553\/jmcp.2022.28.10.1173","article-title":"Real-world use patterns of angiotensin receptor-neprilysin inhibitor (sacubitril\/valsartan) among patients with heart failure within a large integrated health system","volume":"28","author":"Kim","year":"2022","journal-title":"J Manag Care Spec Pharm"},{"key":"2026051414200205900_xvag085-B37","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1001\/jamacardio.2021.0496","article-title":"Simultaneous or rapid sequence initiation of quadruple medical therapy for heart failure-optimizing therapy with the need for speed","volume":"6","author":"Greene","year":"2021","journal-title":"JAMA Cardiol"},{"key":"2026051414200205900_xvag085-B38","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.jchf.2024.08.004","article-title":"Inpatient use of guideline-directed medical therapy during heart failure hospitalizations among community-based health systems","volume":"13","author":"Zheng","year":"2025","journal-title":"JACC Heart Fail"},{"key":"2026051414200205900_xvag085-B39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5837\/bjc.2023.002","article-title":"Evaluating initiation and real-world tolerability of dapagliflozin for the management of HFrEF","volume":"30","author":"Hui","year":"2023","journal-title":"Br J Cardiol"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eschf\/advance-article-pdf\/doi\/10.1093\/eschf\/xvag085\/67423331\/xvag085.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/13\/3\/xvag085\/67423331\/xvag085.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/13\/3\/xvag085\/67423331\/xvag085.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T18:20:10Z","timestamp":1778782810000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/doi\/10.1093\/eschf\/xvag085\/8529720"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,20]]},"references-count":39,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3,20]]},"published-print":{"date-parts":[[2026,5,5]]}},"URL":"https:\/\/doi.org\/10.1093\/eschf\/xvag085","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6]]},"published":{"date-parts":[[2026,3,20]]},"article-number":"xvag085"}}